Breast cancer

Disease ID:160
Name:Breast cancer
Associated with:18 targets
0 immuno-relevant targets
0 immuno-relevant ligands
Database Links
Disease Ontology: DOID:1612
OMIM: 114480

Targets

CCR7
References:  9
CXCR5
Role:  CXCL13-induced CXCR5 activity promotes epithelial to mesenchymal transition in breast cancer cell lines.
References:  2
ADGRB2
Role:  Mutations in ADGRB2 are associated with HER2+, HR+ and triple-negative forms of breast cancer
References:  8
Mutations:  ADGRB2 is associated with 3 mutation. Click here for details
FZD7
Role:  Associated link with triple-negative breast cancer (TNBC)
References:  10,30
NK1 receptor
References:  7,16,18-24
Retinoic acid receptor-β
Role:  Breast cancer is associated with RARb loss-of expression.
References:  25-27,29
Pregnane X receptor
Role:  A significant positive correlation was detected between the SXR/hPXR labeling index and both the histologic grade and the lymph node status of the carcinoma cases
References:  17
Estrogen receptor-α
References:  11
Mutations:  Estrogen receptor-α is associated with 1 mutation. Click here for details
Progesterone receptor
Comments:  PR detection is used to characterized breast tumors, mainly because, as an estrogen receptor target gene, the expression of PR is indicative of a normally functioning estrogen receptor and thus predictive of a favorable patient response to anti-estrogen therapy. In addition, expression of PRB correlates with absence of Her2/Neu, and reduced PRB expression (higher PRA:B ratio) correlates with increased tumor grade.
References:  1
Caspase 8
Role:  A single nucleotide polymorphism in CASP8 is associated with protection against breast cancer.
Mutations:  Caspase 8 is associated with 1 mutation. Click here for details
checkpoint kinase 2
Comments:  Mutations in CHEK2 cause increased susceptibility to breast cancer
regulator of G-protein signaling 16
References:  12,28
Mutations:  regulator of G-protein signaling 16 is associated with 1 mutation. Click here for details
regulator of G-protein signaling 6
Role:  Downregulation of RGS6 in human mammary ductal epithelial cells correlates with cellular transformation and progression to tumorigenesis.
References:  14-15

Ligands

No ligand related data available for Breast cancer

References

Show »

1. Bamberger AM, Milde-Langosch K, Schulte HM, Löning T. (2000) Progesterone receptor isoforms, PR-B and PR-A, in breast cancer: correlations with clinicopathologic tumor parameters and expression of AP-1 factors. Horm. Res., 54 (1): 32-7. [PMID:11182633]

2. Biswas S, Sengupta S, Roy Chowdhury S, Jana S, Mandal G, Mandal PK, Saha N, Malhotra V, Gupta A, Kuprash DV et al.. (2014) CXCL13-CXCR5 co-expression regulates epithelial to mesenchymal transition of breast cancer cells during lymph node metastasis. Breast Cancer Res. Treat., 143 (2): 265-76. [PMID:24337540]

3. Cox A, Dunning AM, Garcia-Closas M, Balasubramanian S, Reed MW, Pooley KA, Scollen S, Baynes C, Ponder BA, Chanock S et al.. (2007) A common coding variant in CASP8 is associated with breast cancer risk. Nat. Genet., 39 (3): 352-8. [PMID:17293864]

4. Dotzlaw H, Leygue E, Watson P, Murphy LC. (1999) The human orphan receptor PXR messenger RNA is expressed in both normal and neoplastic breast tissue. Clin. Cancer Res., 5 (8): 2103-7. [PMID:10473093]

5. Frank B, Bermejo JL, Hemminki K, Klaes R, Bugert P, Wappenschmidt B, Schmutzler RK, Burwinkel B. (2005) Re: Association of a common variant of the CASP8 gene with reduced risk of breast cancer. J. Natl. Cancer Inst., 97 (13): 1012; author reply 1012-3. [PMID:15998955]

6. Fuqua SA, Wiltschke C, Zhang QX, Borg A, Castles CG, Friedrichs WE, Hopp T, Hilsenbeck S, Mohsin S, O'Connell P, Allred DC. (2000) A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions. Cancer Res., 60 (15): 4026-9. [PMID:10945602]

7. Huang WQ, Wang JG, Chen L, Wei HJ, Chen H. (2010) SR140333 counteracts NK-1 mediated cell proliferation in human breast cancer cell line T47D. J. Exp. Clin. Cancer Res., 29: 55. [PMID:20497542]

8. Kan Z, Jaiswal BS, Stinson J, Janakiraman V, Bhatt D, Stern HM, Yue P, Haverty PM, Bourgon R, Zheng J, Moorhead M, Chaudhuri S, Tomsho LP, Peters BA, Pujara K, Cordes S, Davis DP, Carlton VE, Yuan W, Li L, Wang W, Eigenbrot C, Kaminker JS, Eberhard DA, Waring P, Schuster SC, Modrusan Z, Zhang Z, Stokoe D, de Sauvage FJ, Faham M, Seshagiri S. (2010) Diverse somatic mutation patterns and pathway alterations in human cancers. Nature, 466 (7308): 869-73. [PMID:20668451]

9. Kim SJ, Shin JY, Lee KD, Bae YK, Sung KW, Nam SJ, Chun KH. (2012) MicroRNA let-7a suppresses breast cancer cell migration and invasion through downregulation of C-C chemokine receptor type 7. Breast Cancer Res., 14 (1): R14. [PMID:22251626]

10. King TD, Zhang W, Suto MJ, Li Y. (2012) Frizzled7 as an emerging target for cancer therapy. Cell. Signal., 24 (4): 846-51. [PMID:22182510]

11. Lewis JS, Jordan VC. (2005) Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance. Mutat. Res., 591 (1-2): 247-63. [PMID:16083919]

12. Liang G, Bansal G, Xie Z, Druey KM. (2009) RGS16 inhibits breast cancer cell growth by mitigating phosphatidylinositol 3-kinase signaling. J. Biol. Chem., 284 (32): 21719-27. [PMID:19509421]

13. MacPherson G, Healey CS, Teare MD, Balasubramanian SP, Reed MW, Pharoah PD, Ponder BA, Meuth M, Bhattacharyya NP, Cox A. (2004) Association of a common variant of the CASP8 gene with reduced risk of breast cancer. J. Natl. Cancer Inst., 96 (24): 1866-9. [PMID:15601643]

14. Maity B, Stewart A, O'Malley Y, Askeland RW, Sugg SL, Fisher RA. (2013) Regulator of G protein signaling 6 is a novel suppressor of breast tumor initiation and progression. Carcinogenesis, 34 (8): 1747-55. [PMID:23598467]

15. Maity B, Yang J, Huang J, Askeland RW, Bera S, Fisher RA. (2011) Regulator of G protein signaling 6 (RGS6) induces apoptosis via a mitochondrial-dependent pathway not involving its GTPase-activating protein activity. J. Biol. Chem., 286 (2): 1409-19. [PMID:21041304]

16. Mayordomo C, García-Recio S, Ametller E, Fernández-Nogueira P, Pastor-Arroyo EM, Vinyals L, Casas I, Gascón P, Almendro V. (2012) Targeting of substance P induces cancer cell death and decreases the steady state of EGFR and Her2. J. Cell. Physiol., 227 (4): 1358-66. [PMID:21604273]

17. Miki Y, Suzuki T, Kitada K, Yabuki N, Shibuya R, Moriya T, Ishida T, Ohuchi N, Blumberg B, Sasano H. (2006) Expression of the steroid and xenobiotic receptor and its possible target gene, organic anion transporting polypeptide-A, in human breast carcinoma. Cancer Res., 66 (1): 535-42. [PMID:16397270]

18. Muñoz M, Rosso M, Casinello F, Coveñas R. (2010) Paravertebral anesthesia: how substance P and the NK-1 receptor could be involved in regional block and breast cancer recurrence. Breast Cancer Res. Treat., 122 (2): 601-3. [PMID:20333544]

19. Navarro P, Ramkissoon SH, Shah S, Park JM, Murthy RG, Patel SA, Greco SJ, Rameshwar P. (2012) An indirect role for the oncomir-519b in the expression of truncated neurokinin-1 in breast cancer cells. Exp. Cell Res., 318 (20): 2604-15. [PMID:22981979]

20. Palma C. (2006) Tachykinins and their receptors in human malignancies. Curr Drug Targets, 7 (8): 1043-52. [PMID:16918332]

21. Patel HJ, Ramkissoon SH, Patel PS, Rameshwar P. (2005) Transformation of breast cells by truncated neurokinin-1 receptor is secondary to activation by preprotachykinin-A peptides. Proc. Natl. Acad. Sci. U.S.A., 102 (48): 17436-41. [PMID:16291810]

22. Rameshwar P. (2007) Implication of possible therapies targeted for the tachykinergic system with the biology of neurokinin receptors and emerging related proteins. Recent Pat CNS Drug Discov, 2 (1): 79-84. [PMID:18221219]

23. Reddy BY, Greco SJ, Patel PS, Trzaska KA, Rameshwar P. (2009) RE-1-silencing transcription factor shows tumor-suppressor functions and negatively regulates the oncogenic TAC1 in breast cancer cells. Proc. Natl. Acad. Sci. U.S.A., 106 (11): 4408-13. [PMID:19246391]

24. Reddy BY, Trzaska KA, Murthy RG, Navarro P, Rameshwar P. (2008) Neurokinin receptors as potential targets in breast cancer treatment. Curr Drug Discov Technol, 5 (1): 15-9. [PMID:18537563]

25. Widschwendter M, Berger J, Daxenbichler G, Müller-Holzner E, Widschwendter A, Mayr A, Marth C, Zeimet AG. (1997) Loss of retinoic acid receptor beta expression in breast cancer and morphologically normal adjacent tissue but not in the normal breast tissue distant from the cancer. Cancer Res., 57 (19): 4158-61. [PMID:9331065]

26. Widschwendter M, Berger J, Hermann M, Müller HM, Amberger A, Zeschnigk M, Widschwendter A, Abendstein B, Zeimet AG, Daxenbichler G, Marth C. (2000) Methylation and silencing of the retinoic acid receptor-beta2 gene in breast cancer. J. Natl. Cancer Inst., 92 (10): 826-32. [PMID:10814678]

27. Widschwendter M, Berger J, Müller HM, Zeimet AG, Marth C. (2001) Epigenetic downregulation of the retinoic acid receptor-beta2 gene in breast cancer. J Mammary Gland Biol Neoplasia, 6 (2): 193-201. [PMID:11501579]

28. Wiechec E, Overgaard J, Hansen LL. (2008) A fragile site within the HPC1 region at 1q25.3 affecting RGS16, RGSL1, and RGSL2 in human breast carcinomas. Genes Chromosomes Cancer, 47 (9): 766-80. [PMID:18521847]

29. Xu XC, Sneige N, Liu X, Nandagiri R, Lee JJ, Lukmanji F, Hortobagyi G, Lippman SM, Dhingra K, Lotan R. (1997) Progressive decrease in nuclear retinoic acid receptor beta messenger RNA level during breast carcinogenesis. Cancer Res., 57 (22): 4992-6. [PMID:9371489]

30. Yang L, Wu X, Wang Y, Zhang K, Wu J, Yuan YC, Deng X, Chen L, Kim CC, Lau S et al.. (2011) FZD7 has a critical role in cell proliferation in triple negative breast cancer. Oncogene, 30 (43): 4437-46. [PMID:21532620]